6th IAS Conference On HIV Pathogenesis, Treatment and Prevention

NAPWAs' Treatment Horizons: Pathways to a Functional Cure TUSA03

Organiser: National Association of People with AIDS (NAPWA)
Type:
Non-Commercial Satellite Back
Venue: MR 3
Time: 07:00 - 08:30, 19.07.2011
Code: TUSA03
Chairs: Stephen Bailous, France
Frank Oldham Jr., United States

Prominent researchers have not given up looking for a functional cure. In a recent brilliant editorial in The New York Times, Nobel laureate and President-elect of the International AIDS Society Françoise Barré-Sinoussi writes:

I believe that given our current knowledge and innovative tools and concepts, a functional cure is a more realistic goal for the near future.


Top researchers from three continents pursuing a functional cure for HIV/AIDS will present updates at this session.  Presentations include ground breaking research on T-cell based vaccines, therapeutic vaccines and other immune based therapies, as well as next generation antiretrovirals studied for their ability to meet the growing needs of people living with HIV/AIDS who have become resistant to approved HAART regimens.


Presentations include updates from Aphios, Avexa, Bionor Pharma, FIT Biotech, and VIRxSYS.


Resistance to current treatments is reaching a critical mass. People living with HIV/AIDS desperately need a new generation of treatments before resistance makes the current class of anti-retroviral drugs obsolete. New treatments are needed to address the different needs of PLWHAs in developing countries, rural, and underserved communities at higher risk for drug resistance. We can save lives if an emerging, new broad range of therapeutic interventions for HIV/AIDS and co-morbidities are rapidly accelerated.


This second annual NAPWA symposium will offer updates on the largest phase 2b placebo controlled therapeutic vaccine human trial, and data indicating a functional cure - near non-detectable viral loads in the blood and reservoirs of some non-human primates who received a therapeutic vaccine.


A successful therapeutic vaccine would offer significant benefits:
 


·         Reduced risk of drug toxicities for people living with HIV


·         Preservation of immune system function and stimulation of HIV-specific immunity


·         Dramatically lower costs than current HAART drugs


·         Reduced or eliminated HIV in reservoirs and sanctuary regions


·         Easier administration and less dependence on taking pills every day - only a few injections and boosters


·         Progress towards a possible permanent "functional cure" for HIV/AIDS


Founded in 1983 as the largest and oldest advocacy group for people living with HIV/AIDS, NAPWA is the trusted independent voice for all people living with the virus in the United States. NAPWA remains a strong voice in policy, capacity building, leadership development, and social networking. NAPWA is a 501(c) 3 non-profit organization based in Silver Spring, Maryland.  For more information about NAPWA, please visit www.napwa.org.


 




Presentations in this session:

07:00

Powerpoint
Welcome
Presented by Frank Oldham Jr., United States



07:10

Powerpoint
Introduction
Presented by Stephen Bailous, France



07:20

Powerpoint
Bio-K+ to improve health of people living with HIV/AIDS - A safe and effective solution
Presented by Mathieu Millette, Canada



07:30

Powerpoint
Cenicriviroc: A potent dual chemokine receptor antagonist (CCR5/CCR2) in phase 2b development with potential to Transform HIV Treatment
Presented by Sandra M. Palleja, United States



07:40
ATC: Phase 3 data from the AVX-301 study
Presented by Susan Cox, Australia



07:50

Powerpoint
Combination therapy for treating HIV latency
Presented by Trevor P. Castor, United States



08:00

Powerpoint
The therapeutic effect of the FIT-06, GTU-Multi-HIVB DNA vaccine, observed in the HIV-1 infected people - results of a Phase II trial
Presented by Mart Ustav, Finland



08:10

Powerpoint
Vacc4x: a therapeutic HIV-1 vaccine based on modified peptides
Presented by Maja A. Sommerfelt, Norway



08:20

Powerpoint
An HIV-based lentiviral vector vaccine achieves functional cure post-challenges in a subset of vaccinated macaques
Presented by Lawrence Michaelis, United States



08:25
Questions and answers





Powerpoints presentations
Welcome - Frank Oldham Jr.

Introduction - Stephen Bailous

Bio-K+ to improve health of people living with HIV/AIDS - A safe and effective solution - Mathieu Millette

Cenicriviroc: A potent dual chemokine receptor antagonist (CCR5/CCR2) in phase 2b development with potential to Transform HIV Treatment - Sandra M. Palleja


Combination therapy for treating HIV latency - Trevor P. Castor

The therapeutic effect of the FIT-06, GTU-Multi-HIVB DNA vaccine, observed in the HIV-1 infected people - results of a Phase II trial - Mart Ustav

Vacc4x: a therapeutic HIV-1 vaccine based on modified peptides - Maja A. Sommerfelt

An HIV-based lentiviral vector vaccine achieves functional cure post-challenges in a subset of vaccinated macaques - Lawrence Michaelis



   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2011 International AIDS Society